Skip to content
Hanauer Landstrasse 287 · 60314 Frankfurt am Main
Vitamins and supplements next to fresh parsley on table.
Image created with AI
Healthcare & Lifesciences 26. November 2021 · 4 min read

ECJ: Marketing authorisation of medicinal products according to national rules

In its Pharma Expressz ruling, the highest European court confirmed the marketing authorisation of medicinal products according to national rules. This even applies regardless of the fact that it may be sold in another member state without a doctor’s prescription.

Marketing authorisation of medicinal products into EU

Inverkehrbringen von ArzneimittelnImage created with AI

The background to this ruling was a request for a preliminary ruling from Hungary.

As the authority responsible for supervising the placing of medicinal products on the market, the Hungarian Institute found that Pharma Expressz (Pharma Expressz Szolgáltató és Kereskedelmi Kft (Hungary)) had on several occasions imported from another EEA Member State a medicinal product whose placing on the market in Hungary had not been authorised, but which had been released as a non-prescription medicinal product in that other EEA Member State.

The Institute was of the opinion that the use of such a medicinal product for therapeutic purposes should have been notified to it by the prescribing doctor, who in turn had to obtain an opinion on such use. This was because Hungarian law (Section 3(5) of Emberi felhasználásra kerülő gyógyszerek rendeléséről és kiadásáról szóló 44/2004. EszCsM rendele), which applied until 13 February 2018, provided as follows:

“A doctor may prescribe a medicinal product which is not marketed in Hungary but is marketed in a Member State of the EEA in accordance with Section 25(2) of the Medicinal Products Act only if he or she notifies the Institute of the medicinal product before prescribing it and obtains its opinion”.

Before the ECJ, the focus was therefore on the question of whether a national regulation is applicable in the case of sales in pharmacies of a second Member State without a marketing authorisation in that Member State – and this for a non-prescription medicinal product.

National regulations for marketing authorisation

In its ruling, the highest European court confirmed the primacy of national regulations with regard to the marketing authorisation of medicinal products. A requirement under national law to obtain an opinion from the competent authority in order to ensure compliance with the conditions laid down in Art. 5(1) of Directive 2001/83 constitutes a proper transposition of that provision, the ECJ ruled.

Thus, according to the ECJ, if a medicinal product does not have a marketing authorisation granted by the competent authority of the Member State in which it is offered for sale or a marketing authorisation granted under the centralised procedure, it may not be marketed in that State – irrespective of the fact that it may be sold in another Member State without a medical prescription. Not only does the Medicinal Products Directive not require that a medicinal product, the marketing of which as a non-prescription medicinal product has been authorised by one Member State, must also be regarded as a medicinal product not subject to medical prescription by another Member State which has not authorised its marketing, but on the contrary it precludes this possibility.

A medicinal product that is not subject to medical prescription in one Member State may only be marketed in another Member State if that Member State also authorises its marketing, the ECJ ruled.

Marketing authorisation of medicinal products in Hungary

With regard to the Hungarian legislation, the court also made a concluding remark. Apparently, the resulting formalities constituted an exception in Hungarian law allowing, in particular, medical needs, the placing on the market of medicinal products in a Member State even in the absence of a marketing authorisation granted by that State or by the Commission.

However, as Hungary has properly implemented this exception by introducing these formalities, they cannot be classified as a quantitative restriction on imports or a measure having equivalent effect with regard to the principle of the free movement of goods (within the meaning of Article 34 TFEU), the ECJ ruled.

Sources:

ECF jugdement Pharma Expressz, C‑178/20

Image:

JerzyGorecki | pixabay | CCO License

 

Leave a comment

Your email address will not be published. Required fields are marked *.

You might also like

Visit the blog

Image created with AI
11. August 2026 Ozempic Patent Cliff: How Investors Can Profit from the GLP-1 Market After Patent Expiry
EU clinical trials and patent law theme with DNA helix
Image created with AI
22. May 2026 The New EU Transparency Rules for Clinical Trials: Navigating Regulatory Disclosure and Patentability at the EPO and UPC
BPatG Ciclesonid legal case European Union stars scales
Image created with AI
19. May 2026 Veterinary Marketing Authorisation as „First Authorisation” for SPCs: German Federal Patent Court Refers Key Ciclesonide Question to the CJEU
Gelbe Kapseln aus Medikamentenflasche, pharmazeutische Wirkstoffe.
Image created with AI
7. March 2022 BPatG: Patent claim of cancer drug on active substance as salt
Digital human body illustration with visible skeleton and graphs.
Image created with AI
6. December 2021 Bioabsorbable medical devices: Advertising permitted
Chinese flag over assortment of capsules and tablets.
Image created with AI
15. October 2021 Amendments in patent act China relating Pharmacy

Contact us or request a callback

+49 (0) 69 / 606 278 – 0 info@legal-patent.com Request a callback